Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tamsulosin OCAS 0.4 mg for nocturia in LUTS associated with BPH
2005-001627-11Phase 4Completed
- Sponsor
- Astellas Pharma
- Start
- Jul 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in benign prostatic hyperplasia (BPH) and nocturia comparing Tamsulosin OCAS 0.4 mg once daily with Placebo once daily (2 arms). Primary endpoint: Change in mean number of nocturnal voids. Started Jul 2005; status: completed.
02
Drugs
tamsulosin
03
Conditions
benign prostatic hyperplasia (BPH)nocturia
Beyond the preview
Go deeper on 2005-001627-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001627-11.